Magellan Longevity grades every product it lists on the strength of the human evidence behind it, and links each grade to the primary literature it rests on. This dataset is that entire judgement, exported in full and given away: 130 products with their grade, the reason for the grade, the caveat that qualifies it, the dose actually used in human trials, the mechanistic pathway, and every PubMed identifier behind it — plus a second table of 2692 study-level records covering 2646 distinct PubMed identifiers and 2346 DOIs.
It exists because evidence grading in consumer health is almost always a black box. Sites publish a badge and never publish the reasoning, the citation list, or the cases where the evidence went the other way. Everything here is machine-readable and auditable, including the 1 product graded “Tested — did not work” and the 144 study records whose own conclusion reports no difference. Null results are part of the dataset by design — a catalogue that only ever surfaces flattering studies is marketing in a lab coat.
The grades in this file are not a re-derivation for publication. They are produced by executing the exact grading code that renders the live product pages, so the dataset cannot drift from what a reader sees on the site.
Every file is UTF-8, licensed CC BY 4.0, and free. CSVs follow RFC 4180. The two tables share an identical schema across all three formats — the JSON and JSONL are not reduced versions of the CSV.
| File | Table | Rows | Fields | Size | SHA-256 (first 16) |
|---|---|---|---|---|---|
| products.csv | products | 130 | 32 | 230 KB | a89ee19e4cba9e88 |
| products.json | products | 130 | 32 | 324 KB | 79311cf951f2936f |
| products.jsonl | products | 130 | 32 | 307 KB | 435208675fa8185c |
| studies.csv | studies | 2692 | 32 | 2.1 MB | 113ed23822b0aff1 |
| studies.json | studies | 2692 | 32 | 3.9 MB | 22cdcc06203226e8 |
| studies.jsonl | studies | 2692 | 32 | 3.6 MB | e22d1b73d4274a28 |
Supporting files: data-dictionary.json · data-dictionary.md · dictionary as a web page · datapackage.json (Frictionless) · dataset-metadata.json (schema.org) · CITATION.cff · citation.bib · citation.ris · LICENSE.txt · checksums.txt · README.md
# verify what you downloaded
sha256sum -c checksums.txt
# 10 strongest-evidence products, straight from the CSV
python3 -c "import csv;[print(r['evidence_grade'],r['product_name'])\
for r in csv.DictReader(open('products.csv')) if r['evidence_tier_key']=='strong']"products (130 rows × 32 fields)One row per catalogue product. Beyond identity and category it carries evidence_grade, grade_rationale, grade_caveat, studied_dose and dietary_dose, pathway_name, citation_count, the semicolon-separated pmids, and study_keys to join into table 2. A verbatim key_finding_quote records the single sentence used to justify the pathway assignment — quoted, never paraphrased into a stronger claim.
studies (2692 rows × 32 fields)One row per study record: pmid, doi, journal, year, title, the compound it supports, the outcome in the source's own words, and reported_direction — a coarse rule-based reading of which way the source itself says the result went. 314 rows also carry a full structured write-up: research question, hypothesis, methods, results, conclusion and stated limitations. Filter is_primary_record_for_pmid to reduce the table to 2646 unique papers.
Join: products.study_keys → split on ; → studies.study_key. The full field-by-field dictionary is at /data/data-dictionary.html.
A single dependency-free Node script (tools/build_dataset.js) reads five files from the live site and writes every artefact on this page. Nothing is hand-edited between generation and publication, and no number on this page is typed by hand — each one is computed at build time.
| Source | What is taken from it |
|---|---|
data.js | The catalogue: products, categories, compound monographs and the full study index. |
study-writeups.js | 314 structured study write-ups (question, hypothesis, methods, results, conclusion, limitations, takeaway). |
dosedata.js | Per-compound dose actually used in human trials, and the dose obtainable from food. |
index.html | The grading rubric and the grading function itself — extracted and executed, so the exported grade is byte-for-byte the grade the site renders. |
sitemap.xml | The authoritative list of live monograph URLs, so no row links anywhere that does not exist. |
Empty means not recorded in the source. No value is imputed, rounded up, or filled in from memory: where the catalogue has no DOI, the DOI cell is blank; where no human dose range has been established, studied_dose is blank rather than guessed.
Ingestibles and interventions are graded on the strength of human evidence for the active compound. Diagnostics and wearables are graded on how well the thing they measure predicts health — not on a treatment effect. These are the tier definitions exactly as published on the site, with the number of products that currently sit in each.
| Tier | Letter | Definition | Products |
|---|---|---|---|
| Strong evidence | A | Consistent randomized human trials — or large, convergent human cohort data, sometimes backed by genetic (Mendelian) evidence — show a real benefit. That benefit is often a specific, measurable outcome (blood pressure, blood glucose, joint pain, muscle strength) rather than proof of a longer lifespan; each product’s page and caveat say exactly what the strong evidence is <i>for</i>. | 11 |
| Moderate evidence | B | Several human studies point the same way, but with limits — size, duration, funding, or mixed results. | 74 |
| Emerging evidence | C | Mechanism is plausible and early human data exists, but it is small, short, or not yet replicated. | 20 |
| Preliminary | C- | Mostly mechanistic or animal data, or very few human studies. Interesting, not proven. | 4 |
| Measurement tool | B | A test or sensor. Graded on what the marker predicts and how reliably it measures it. | 20 |
| Tested — did not work | D | Adequately tested in humans and the result was negative. This is not thin evidence — it is sufficient evidence pointing at no benefit, which is why it is graded below Preliminary rather than above it. | 1 |
For well-characterized compounds, a board-certified physician assigns the grade from the human and mechanistic literature, and we publish a typical dose only where a verified standard range exists. For the long tail of ingredients, the grade is derived conservatively from the peer-reviewed studies we link on the page, and is capped below “Strong” until it has been individually reviewed. Effect statements shown on product pages are quoted verbatim from a cited study — we never paraphrase findings into stronger claims than the authors made.
We show null and negative evidence too. Where human trials are inconsistent or have failed to show benefit, we say so on the product page. A marketplace that only ever surfaces flattering studies is marketing in a lab coat.
Editorial firewall. Inclusion is never paid. No brand can buy a listing, a grade, or placement. We are not sponsored by and do not sell our own supplement line — so we are never stuck defending a bottle we make.
Each grade also carries how it was reached: curated_compound (104), curated_product (26). Open the full methodology in the Magellan store →
These are the aggregate numbers a reader or a journalist would want before citing anything. All are computed from the released files.
| Grade | Products | Share | Median citations per product |
|---|---|---|---|
| Strong evidence | 11 | 8.5% | 20 |
| Moderate evidence | 74 | 56.9% | 21 |
| Emerging evidence | 20 | 15.4% | 21 |
| Preliminary | 4 | 3.1% | 21 |
| Measurement tool | 20 | 15.4% | 22 |
| Tested — did not work | 1 | 0.8% | 22 |
Across the catalogue the median product carries 21 peer-reviewed citations; the total number of product-to-study links is 3421.
| Reported direction | Study rows | Share |
|---|---|---|
favorable | 971 | 36.1% |
mixed | 97 | 3.6% |
no_difference | 144 | 5.3% |
unfavorable | 115 | 4.3% |
unclear | 1365 | 50.7% |
Read this honestly. reported_direction is a deterministic keyword cascade over the source's own summary sentence, not an appraisal and not a language model. unclear (50.7% of rows) means no cue matched — usually a descriptive or mechanistic conclusion — and must not be read as a null result. Every classified row carries direction_evidence, the exact phrase that triggered it, so you can audit or discard any row. The rule set is documented in full in the data dictionary.
| Period | Study rows | Share |
|---|---|---|
| before 2000 | 51 | 1.9% |
| 2000–2009 | 270 | 10.0% |
| 2010–2014 | 326 | 12.1% |
| 2015–2019 | 706 | 26.2% |
| 2020–2022 | 660 | 24.5% |
| 2023–2024 | 449 | 16.7% |
| 2025 and later | 230 | 8.5% |
Range 1971–2026, median 2019, across 2692 rows carrying a year.
| Journal | Study rows |
|---|---|
| Nutrients | 112 |
| Am J Clin Nutr | 41 |
| Cochrane Database Syst Rev | 38 |
| J Cosmet Dermatol | 33 |
| Phytother Res | 25 |
| PLoS One | 25 |
| Sci Rep | 21 |
| Int J Environ Res Public Health | 19 |
| BMJ | 18 |
| Br J Nutr | 17 |
| JAMA | 17 |
| N Engl J Med | 16 |
1153 distinct journals appear in the dataset.
| Pathway | Products |
|---|---|
| Cardiovascular & Vascular | 20 |
| Muscle & Bone | 15 |
| Circadian & Stress | 14 |
| Biomarkers & Biological Age | 11 |
| Connective Tissue | 11 |
| Redox / Antioxidant | 10 |
| NAD⁺ / Sirtuin Axis | 9 |
| Environmental Exposure | 7 |
| Gut–Immune Axis | 7 |
| AMPK / Metabolic | 5 |
| Brain & Cognition | 3 |
| Mitochondrial Energy | 3 |
24 distinct pathways in total — the pathway taxonomy is rendered visually at /pathway-universe.html.
Fifteen rows from products.csv, strongest evidence first. The full table of all 130 rows is browsable at /data/evidence-grades.html.
| Product | Grade | Pathway | Citations | Studied dose |
|---|---|---|---|---|
| Creatine Monohydrate | Strong evidence | Muscle & Bone | 23 | 3–5 g/day (creatine monohydrate); an optional ~20 g/day loading week works faster but… |
| Betaine (TMG) | Strong evidence | Epigenetic / TCA | 23 | 1.5–6 g/day in trials |
| Bright Light Therapy Lamp | Strong evidence | Circadian & Stress | 21 | ~10,000 lux white light for ~30 min each morning |
| Hand Grip Dynamometer Pro | Strong evidence | Muscle & Bone | 21 | — |
| Lutein and Zeaxanthin | Strong evidence | Brain & Cognition | 21 | 10 mg lutein + 2 mg zeaxanthin daily (the AREDS2 formulation) |
| Validated Home BP Monitor | Strong evidence | Cardiovascular & Vascular | 20 | — |
| Azelaic Acid Gel | Strong evidence | Gut–Immune Axis | 20 | 15-20% topical gel/cream (prescription strengths used in most trials) |
| Daily Mineral SPF Sunscreen | Strong evidence | Connective Tissue | 19 | Daily broad-spectrum SPF 15 or higher, applied in adequate amounts |
| Balance and Strength Trainer | Strong evidence | Muscle & Bone | 19 | Balance-challenging exercise ~3+ hours/week; strength training ~30–60 min/week |
| 24h Ambulatory BP Monitor | Strong evidence | Cardiovascular & Vascular | 19 | — |
| Voltaren Arthritis Pain Gel (Diclofenac 1%) | Strong evidence | NSAID / Prostaglandin | 17 | 1% gel (~2–4 g) over the joint up to 4×/day; relief builds over ~7 days |
| Double Wood NMN Capsules | Moderate evidence | NAD⁺ / Sirtuin Axis | 34 | Human RCTs used 250–1,200 mg/day orally; well-tolerated up to ~900 mg/day, with one… |
| Nutricost NMN Capsules 500mg | Moderate evidence | NAD⁺ / Sirtuin Axis | 34 | Human RCTs used 250–1,200 mg/day orally; well-tolerated up to ~900 mg/day, with one… |
| NOVOS Boost NMN | Moderate evidence | NAD⁺ / Sirtuin Axis | 34 | Human RCTs used 250–1,200 mg/day orally; well-tolerated up to ~900 mg/day, with one… |
| NMN Complex 1000 mg (Micro Ingredients) | Moderate evidence | NAD⁺ / Sirtuin Axis | 34 | Human RCTs used 250–1,200 mg/day orally; well-tolerated up to ~900 mg/day, with one… |
reported_direction is derived, not curated. It is a published rule cascade over the source's own words. 1365 rows are unclear because no rule fired; that is not evidence of absence.primary_compound. They are retained rather than dropped so the table reconciles exactly against the source catalogue.is_primary_record_for_pmid to collapse them.Released under the Creative Commons Attribution 4.0 International (CC BY 4.0). You may share and adapt it for any purpose, including commercially. You must give credit, link to the licence, and indicate whether you made changes. In practice that means: if you use these grades or this citation graph, name the source and link back.
Radu, G. (2026). Magellan Longevity Open Evidence Dataset (Version 1.0.0) [Data set]. Magellan Longevity. https://magellanlongevity.com/data/@dataset{magellan_longevity_evidence_2026, author = {Radu, Gabriel}, title = {Magellan Longevity Open Evidence Dataset}, year = {2026}, version = {1.0.0}, publisher = {Magellan Longevity}, url = {https://magellanlongevity.com/data/}, license = {CC-BY-4.0}, note = {130 graded longevity products and 2692 linked study records} }Magellan Longevity Open Evidence Dataset v1.0.0 (Gabriel Radu, DO, 2026), https://magellanlongevity.com/data/ — CC BY 4.0Machine-readable citation metadata: CITATION.cff, BibTeX, RIS. Third-party article titles, journal names and short quoted findings remain subject to their publishers' terms; no full texts or complete abstracts are redistributed.
v1.0.0 — 2026-08-11. First public release: 130 product rows, 2692 study rows, 2646 distinct PubMed identifiers. Schema frozen at 32 product fields and 32 study fields.
Releases are semantic: a patch changes values only, a minor release adds fields or rows, a major release changes or removes a field. Every release ships its own checksums.txt so a downstream user can prove which cut they analysed.
The same citation graph rendered as a browsable map instead of a CSV.
The 24 mechanistic pathways in pathway_name, visualised.
The narrative version of table 1, written for readers rather than machines.
A worked example: how one compound's row is assembled from its trials.
One of the 11 entries carrying the Strong evidence tier.
Where the mechanistic case runs far ahead of the human data.
Strong cohort data, a null 12-month trial — both kept in the dataset.
A large, well-replicated literature and where its limits are.
Metformin-like effect sizes, small and short trials.
Yes. It is published under Creative Commons Attribution 4.0 International (CC BY 4.0), which permits sharing and adaptation for any purpose including commercial use, provided you credit Gabriel Radu, DO / Magellan Longevity, link to the licence, and state whether you changed anything.
For well-characterized compounds, a board-certified physician assigns the grade from the human and mechanistic literature, and we publish a typical dose only where a verified standard range exists. For the long tail of ingredients, the grade is derived conservatively from the peer-reviewed studies we link on the page, and is capped below “Strong” until it has been individually reviewed. Effect statements shown on product pages are quoted verbatim from a cited study — we never paraphrase findings into stronger claims than the authors made.
No. Inclusion is never paid. No brand can buy a listing, a grade, or placement. We are not sponsored by and do not sell our own supplement line — so we are never stuck defending a bottle we make. Every row carries a grade_caveat field that states the limits of the evidence, and null and negative results are kept in the dataset rather than filtered out.
Version 1.0.0 was cut on 2026-08-11. The literature it draws on spans 1971 to 2026, with a median publication year of 2019. Prices are a snapshot from the release date and should not be treated as live.
No, and it should not be cited as one. It is a transparent catalogue-level evidence map: it records which papers the site relies on for each product, what those papers concluded in their own words, and how strong that body of evidence was judged to be. It does not apply GRADE, does not perform meta-analysis, and does not claim exhaustive literature capture.
Scientific content is reviewed by Gabriel Radu, DO, a board-certified physiatrist (NY licence 275110, NPI 1376861765). See the methodology page in the store →